See this page online at: http://www.biotechfocus.com/Patents
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
April 20 2010
Clinical Trials & Patents Advitech Inc. (Québec, QC) announces that the Natural Health Products Directorate.
Allon Therapeutics Inc. (Vancouver, BC) announces that a Phase 1 clinical trial of its lead neuroprotective drug. Lorus Therapeutics Inc. (Toronto, ON) announces the allowance of an Australian patent. |
|
October 19 2009
Oncolytics Biotech Inc. (Calgary, AB) has been issued a new U.S. patent Oncolytics Biotech Inc. (Calgary, AB) has been issued a new U.S. patent, covering the use of a modified parapoxvirus orf virus to treat Ras-mediated cancers.
|
|
October 19 2009
Héma-Québec (Montréal, QC) has been issued a patent by the European Patent office Héma-Québec (Montréal, QC) has been issued a patent by the European Patent office for the fractionation of therapeutic intravenous immunoglobulin from human plasma.
|
|
September 10 2009
Lorus Therapeutics Inc. (Toronto, ON) for the drug LOR-2040 has been given an allowance in Japan.
|
|
September 10 2009
OncoGenex Pharmaceuticals Inc. (Vancouver, BC) has received a key patent for its lead cancer drug candidate, OGX-011.
|
|
September 10 2009
SemBioSys Genetics Inc. (Calgary, AB) has been granted a U.S. patent for their work on producing insulin in plants.
|
|
July 14 2009
Allon Therapeutics Inc. announces that the European Patent Office has issued a notice of allowance Allon Therapeutics Inc. (Vancouver, BC) announces that the European Patent Office has issued a notice of allowance for a patent covering the composition and method of use of the company’s lead neuroprotective compound davenutide (NAP) as a treatment for Alzheimer’s disease.
|
|
April 14 2009
AstraZeneca (Mississauga, ON) licenses a compound for depression AstraZeneca (Mississauga, ON) licenses a compound for depression discovered by researchers at Virginia Tech and Mayo Clinic.
|
|
April 14 2009
Paladin Labs Inc. (Montreal, QC) has filed a new drug submission for TRELSTAR 22.5 mg Paladin Labs Inc. (Montreal, QC) has filed a new drug submission for TRELSTAR 22.5 mg (triptorelin pamoate for injectible suspension).
|
|
April 14 2009
Oncolytics Biotech Inc. (Calgary, AB) announces that it has been granted its 31st U.S. Patent Oncolytics Biotech Inc. (Calgary, AB) announces that it has been granted its 31st U.S. Patent, No. 7,476,382, entitled “Reovirus for the Treatment of Neoplasia.”
|
|
November 14 2008
Supreme Court decision will keep biotech sector competitive The Supreme Court’s unanimous decision to uphold selection patents, helps keep the biotechnology sector competitive as it seeks international investment during difficult economic times, in view of BIOTECanada, an intervener in the case.
|
|
November 10 2008
Clinical Trials & Patents Cytochroma (Markham, ON) announces the initiation of a Phase II clinical trial for its CTA018 injection.
BioMS Corporation (Edmonton, AB) announces that its Phase II MINDSET-01 trial of dirucotide (MBP8298) in patients with relapsing-remitting MS has been recommended for continuation by the independent Data Safety Monitoring Board (DSMB). Chemokine Therapeutics Corporation (Vancouver, BC) receives a certificate for clinical trial/medicinal test. MethylGene Inc. (Montreal, QC) announces the results of an internal voluntary suspension on enrollment of new patients into clinical trials evaluating MGCD0103. |
|
November 07 2008
Waterloo Region – a leader in R&D expenditures and patents granted Data released on private and public R&D and on patents granted by the US Patent and Trademark office shows that the Waterloo Region is a world-class centre for innovation.
|
|
September 12 2008
Landmark study reports breakdown in biotech patent system The world’s intellectual property system is broken, stopping lifesaving technologies from reaching the people who need them most in developed and developing countries, according to a report released in Ottawa today by an international coalition of experts.
|
|
September 05 2008
New report finds significant flaws in worldwide biotech patenting system Ownership of innovative ideas in most nations rests on the notion that intellectual property is to be tightly held and not shared. As a result, fewer and fewer people - whether in rich countries or poor - have access to the best that breakthroughs in biotechnology have to offer.
|
|
August 26 2008
Stem Cell Therapeutics Corp. (Calgary, AB) Stem Cell Therapeutics Corp. (Calgary, AB) announces that it has been granted U.S. patent no. 7,393,830.
|
|
August 22 2008
Chemokine Therapeutics (Vancouver, BC) Chemokine Therapeutics (Vancouver, BC) has been granted U.S. Patent No. 7,378,098 entitled “CXC Chemokine Receptor 4 Agonist Peptides”.
|
|
August 05 2008
Lorus announces allowance of new U.S. patent for its anticancer drug Lorus Therapeutics Inc. announces the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040.
|
|
March 31 2008
Covalon receives Canadian patent for drug delivery via therapeutic hydrogels Covalon Technologies Ltd. receives a Notice of Allowance for a Canadian patent entitled: Drug delivery via therapeutic hydrogels (Patent Application No. 2,286,644).
|
|
March 25 2008
Theratechnologies (Montreal, QC) Theratechnologies (Montreal, QC) announces that the United States Patent and Trademark Office has issued Patent Number 7,316,997 entitled “GH Secretagogues and Uses Thereof” to Theratechnologies.
|
|
March 14 2008
enGene announces issuance of core US patent enGene Inc. announces that the U.S. Patent and Trademark office has issued US Patent 7, 335, 646, granting enGene claim to a method to induce endocrine cells located in the gastrointestinal tract to synthesize and secrete different therapeutic proteins for the treatment of diabetes and obesity.
|
|
March 14 2008
Inclinix announces new patent for expert system platform Inclinix Inc. receives a patent for its Expert System Platform (ESP), a software system that guides interview questions during patient qualification for clinical trials of new drugs or medical devices.
|
|
November 15 2007
Paladin submits patent application for Thinsol Paladin submits a patent application for Thinsol, a novel oral ingestible film composition delivery system.
|
|
November 02 2007
ART is granted key patent for imaging of breast physiology Advanced Research Technologies Inc. announces that a U.S. patent has been issued for optimal selection of SoftScan optical wavelengths.
|
|
July 26 2007
Urodynamix files for patents Urodynamix Technologies Ltd. has filed a series of applications with the United States Patent and Trademark Office for inventions related to medical applications of near-infrared spectroscopy, the core technology behind the company's URO-NIRS platform.
|
|
July 26 2007
Arius announces issuance of two U.S. patents Arius Research Inc. has been granted two U.S. patents for antibodies within its CD44 Stem Cell Program and its CD59 Complement Inhibitor Program.
|
|
June 14 2007
Allon granted US patent for composition of matter Allon Therapeutics announces that it has been granted a US patent covering additional composition of matter for the products in the ADNP platform, which broadens the intellectual property of Allon's patent portfolio.
|
|
June 01 2007
Queen's-developed decontamination system for chemical warfare agents issued U.S. patent A non-toxic method for decomposing chemical warfare agents discovered at Queen's University has been issued a U.S. patent. The patent was issued under number 7,214,836 on May 8, 2007 and is classified as a Method for Decomposing Organophosphorus Compounds.
|
|
April 23 2007
Patents broadly protect core technology behind chemokine-based therapeutic platform Osprey Pharmaceuticals Limited announces that it has been granted three patents by the U.S. Patent Office. The patents protect the use of conjugated chemokines to selectively and systematically eliminate overactive leukocytes implicated in most chronic diseases, the core technology behind Osprey's Leukocyte Population Modulator (LPM) platform.
|
|
February 12 2007
Axela Biosensors Inc. to license patented technology Axela Biosensors Inc. and Beckman Coulter Inc announces the signing of a nonexclusive licensing agreement, giving Axela rights to Beckman Coulter's patented A(2)(R) Universal Linker Capture Technology. The terms of the license were not disclosed.
|
|
February 12 2007
Isotechnika receives European patent for lead immunosuppressive drug Isotechnika Inc. announces that the company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247.
|
|
November 27 2006
University of Texas Grants License The University of Texas Southwestern Medical Center at Dallas has granted Covalon Technologies Ltd. a non-exclusive license for technology covered by a U.S. patent entitled "Endothelial PAS Domain Protein" (EPAS1).
|
|
November 02 2006
PainCeptor Pharma Corp. Receives Four Patents PainCeptor Pharma Corp. (Montreal, QC) received four patents for two of its drug development programs.
|
|
November 02 2006
YM BioSciences Clears US Cuban Import Restriction The U.S. Treasury Department's Office of Foreign Assets Control (OFAC) has approved a license allowing a U.S. subsidiary of YM BioSciences Inc. to import nimotuzumab from Cuba for the purpose of clinical trials in pediatric patients with pontine glioma.
|
|
October 02 2006
Allon granted Australian patent for new learning and memory compound Allon Therapeutics is continuing to develop unique compounds and related technology to treat the causes of more than nine brain diseases and conditions, including Alzheimers disease and mild cognitive impairment (MCI).
|
|
September 29 2006
Wex Pharmaceuticals Inc. Has Received Two Patents Wex Pharmaceuticals Inc. has received two patents, one from China and the other from the Ukraine.
|
|
July 05 2006
Stem Cell Therapeutics Inc. Receives Patent Stem Cell Therapeutics Inc., a subsidiary of Calgary-based Stem Cell Therapeutics Corp., has received a patent from the U.S. Patent and Trademark Office for combined regulation of neural cell production.
|
|
April 18 2006
Inovio Biomedical Granted Two New Patents Inovio Biomedical Corp. (San Diego, CA) has been granted two new patents -"Method for Muscle Delivery of Drugs, Nucleic Acids and Other Compounds," and "Enhanced Delivery of Naked DNA to Skin by Non-Invasive In Vivo Electroporation" - relating to the use of electroporation to deliver therapeutic agents.
|
|
February 06 2006
ASKED & ANSWERED Compiled by Amber Lepage-Monette Many academic institutions and some biotechnology companies develop new research tools during the course of their R&D programs.
|
|
January 01 2006
iCo Therapeutics Creates Strategic Team Vancover, B.C.-based iCo Therapeutics Inc. has created a Strategic Advisory Team that will assist management and the board of directors manage the company's growth and development.
|
|
September 13 2005
Asked & Answered Compiled by Amber Lepage-Monette This month's question was provided by students from the MBA program at the University of Alberta (Edmonton, AB).
How significant is the gap between university funding of discovery and applied research? How can this gap be bridged to focus a greater portion of research to the development of prototypes and other applications of new discoveries? |
|
June 14 2005
Post-marketing Observational Studies by John Sampalis, PhD Providing insight into real-life clinical practice regarding safety, efficacy and patients' drug compliance.
|
|
May 10 2005
Asked & Answered Compiled by Amber Lepage-Monette The following question was provided by students from the MBA program at the University of Alberta (Edmonton, AB).
In academia there is a recognized mantra: "publish or perish." However, in the development of IP, the mantra is "publish and perish" since publishing severely impairs one's ability to patent. |
|
March 07 2005
Cost-saving Patent Strategies for Small and New Companies By Jennifer Jannuska and Lenni Carreiro The pressure to get patents has never been greater for small and new companies. Patents are the hard currency of research-based businesses. Investors want to see them, competitors have them and companies need them - for licensing, leveraging, litigating and (occasionally) liquidating.
|
|
November 12 2004
Asked & Answered Compiled by Amber Lepage-Monette Over the past decade there has been a dramatic increase in expenditures to obtain and enforce patents for pharmaceutical applications. Cases exist where local and foreign governments have disregarded patent laws to allow for the delivery of pharmaceutical/medical services at an affordable price.
|
|
November 07 2004
Ecopia BioSciences Receives Patent for its Decipher® Technology St-Laurent, Que.-based Ecopia BioSciences Inc. has received a patent on its Decipher® technology from the Canadian Patent Office.
|
|
September 20 2004
ASKED & ANSWERED Compiled by Amber Lepage-Monette Among the major developed countries, significant uncertainty characterizes Canadian patent law with respect to living organisms.
|
|
May 14 2004
Asked & Answered Compiled by Amber Lepage-Monette Understanding firm performance is important to strategy development and firm operations.
|
|
February 16 2004
ASKED & ANSWERED Compiled by Amber Lepage-Monette THIS ISSUE'S ASKED & ANSWERED QUESTION WAS PROVIDED BY THE MEMBERS OF THE BIOPHARMA STUDENT GROUP IN THE QUEENS UNIVERSITY (KINGSTON, ON) MBA FOR SCIENCE & TECHNOLOGY PROGRAM AND THE PROGRAM DIRECTOR JEFF McGILL, PhD.
|
|
September 01 2003
Intellectual Property Disputes BY ANDREW M. SHAUGHNESSY AND CONOR D.M. MCCOURT Consider this: you are the business development manager of a small biotech company with responsibility for commercializing your company's technology. Your breakthrough product has recently emerged from successful Phase III clinical trials and has been protected since its infancy with patent applications across the world.
|
|
January 02 2003
Is Your Patent Portfolio Ready for Due Diligence? By Micheline Gravelle Like death and taxes, due diligence on a biotechnology company's patent portfolio is a certainty. Few biotechnology companies can bring a product to market without receiving venture capital and/or partnering with a larger company.
|
